Switch theme
Sign up to access all valuation multiples
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
1980
28K+
LTM Revenue $34.2B
LTM EBITDA $19.1B
$204B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Amgen has a last 12-month revenue (LTM) of $34.2B and a last 12-month EBITDA of $19.1B.
In the most recent fiscal year, Amgen achieved revenue of $33.4B and an EBITDA of $13.4B.
Amgen expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Amgen valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $34.2B | XXX | $33.4B | XXX | XXX | XXX |
| Gross Profit | $28.3B | XXX | $20.6B | XXX | XXX | XXX |
| Gross Margin | 83% | XXX | 62% | XXX | XXX | XXX |
| EBITDA | $19.1B | XXX | $13.4B | XXX | XXX | XXX |
| EBITDA Margin | 56% | XXX | 40% | XXX | XXX | XXX |
| EBIT | $15.3B | XXX | $7.3B | XXX | XXX | XXX |
| EBIT Margin | 45% | XXX | 22% | XXX | XXX | XXX |
| Net Profit | $11.0B | XXX | $4.1B | XXX | XXX | XXX |
| Net Margin | 32% | XXX | 12% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $48.1B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of June 2, 2025, Amgen's stock price is $288.
Amgen has current market cap of $155B, and EV of $204B.
See Amgen trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $204B | $155B | XXX | XXX | XXX | XXX | $20.27 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of June 2, 2025, Amgen has market cap of $155B and EV of $204B.
Amgen's trades at 6.1x EV/Revenue multiple, and 15.2x EV/EBITDA.
Equity research analysts estimate Amgen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Amgen has a P/E ratio of 14.1x.
See valuation multiples for Amgen and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $155B | XXX | $155B | XXX | XXX | XXX |
| EV (current) | $204B | XXX | $204B | XXX | XXX | XXX |
| EV/Revenue | 6.0x | XXX | 6.1x | XXX | XXX | XXX |
| EV/EBITDA | 10.6x | XXX | 15.2x | XXX | XXX | XXX |
| EV/EBIT | 13.3x | XXX | 28.0x | XXX | XXX | XXX |
| EV/Gross Profit | 7.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 14.1x | XXX | 37.9x | XXX | XXX | XXX |
| EV/FCF | 14.5x | XXX | 19.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAmgen's last 12 month revenue growth is 4%
Amgen's revenue per employee in the last FY averaged $1.2M, while opex per employee averaged $0.5M for the same period.
Amgen's rule of 40 is 56% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Amgen's rule of X is 66% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Amgen and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 56% | XXX | 40% | XXX | XXX | XXX |
| EBITDA Growth | -9% | XXX | 9% | XXX | XXX | XXX |
| Rule of 40 | 56% | XXX | 44% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 66% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 18% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 40% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Amgen acquired XXX companies to date.
Last acquisition by Amgen was XXXXXXXX, XXXXX XXXXX XXXXXX . Amgen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Amgen founded? | Amgen was founded in 1980. |
| Where is Amgen headquartered? | Amgen is headquartered in United States of America. |
| How many employees does Amgen have? | As of today, Amgen has 28K+ employees. |
| Who is the CEO of Amgen? | Amgen's CEO is Mr. Robert A. Bradway. |
| Is Amgen publicy listed? | Yes, Amgen is a public company listed on NAS. |
| What is the stock symbol of Amgen? | Amgen trades under AMGN ticker. |
| When did Amgen go public? | Amgen went public in 1983. |
| Who are competitors of Amgen? | Similar companies to Amgen include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Amgen? | Amgen's current market cap is $155B |
| What is the current revenue of Amgen? | Amgen's last 12 months revenue is $34.2B. |
| What is the current revenue growth of Amgen? | Amgen revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Amgen? | Current revenue multiple of Amgen is 6.0x. |
| Is Amgen profitable? | Yes, Amgen is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Amgen? | Amgen's last 12 months EBITDA is $19.1B. |
| What is Amgen's EBITDA margin? | Amgen's last 12 months EBITDA margin is 56%. |
| What is the current EV/EBITDA multiple of Amgen? | Current EBITDA multiple of Amgen is 10.6x. |
| What is the current FCF of Amgen? | Amgen's last 12 months FCF is $14.1B. |
| What is Amgen's FCF margin? | Amgen's last 12 months FCF margin is 41%. |
| What is the current EV/FCF multiple of Amgen? | Current FCF multiple of Amgen is 14.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
